← All trials
NCT02721420
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2016
- Primary completion
- Mar 1, 2019
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 375
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- University of MalawiLead sponsor
- University of MalawiOverall official - principal investigator
- University of BergenCollaborator
- Makerere UniversityCollaborator
- Kenya Medical Research InstituteCollaborator
- University of LondonCollaborator
- University of LiverpoolCollaborator
- University of MinnesotaCollaborator
- Government of NorwayCollaborator
- Government of MalawiCollaborator
- University of AmsterdamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.